Our trackable CAR T cell therapy targeting intercellular adhesion molecule 1 (ICAM-1) is currently being evaluated in a Phase 1 trial against advanced thyroid cancer (ATC) for safety and the feasibility of CAR T cell imaging using 68Ga-DOTATATE (ClinicalTrials.gov Identifier: NCT04420754). The gene discussed is ICAM1; the disease is thyroid gland carcinoma.